MedWatch

ALK bets on well-known tablet technology to treat peanut allergy

ALK has gotten the rights to use a technology by partner Catalent to develop a peanut allergy tablet vaccine. But the Danish allergy company is far from alone on the food allergy market, where biotech firms have been testing a vast array of different technologies in recent years. Still, CEO Carsten Hellmann brushes off competition.

ALK is betting big on peanut allergy | Photo: ALK / PR

ALK has secured the rights to a technology it will use to develop a tablet against peanut allergy, which will be one of the most important growth drivers in the years post-2025, according to the Danish allergy company.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs